Abstract 763P
Background
Anlotinib is a novel multi-target tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. Penpulimab is a novel human immunoglobulin G1 (IgG1) anti-programmed cell death-1 (PD-1) antibody. ALTN-AK105-II-06 (ChiCTR2200062897) aimed to assess the effiacy and safety of penpulimab + anlotinib plus chemo-less therapy as fist-line therapy for persistent, recurrent, or metastatic cervical cancer.
Methods
Eligible adults with persistent, recurrent, or metastatic cervical cancer not previously treated with systemic chemotherapy and not amenable curative treatment, with CPS more than 1% PD-L1 expression, and ECOG 0-1 were considered eligible for enrolment. Patients received 2 cycles of chemotherapy (paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5) + penpulimab 200mg Q3W + anlotinib 10mg, following with penpulimab and anlotinib for maintenance therapy. Patients were treated on continuous 3 weeks of penpulimab for up to 2 years, until disease progression, or unacceptable toxicities. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), overall survival (OS), 6-month PFS, safety and quality of life.
Results
From Sep 2022 to May 2023, 15 patients were recruited with a median age of 47 years (range: 44-66), FIGO histopathological stage IIB (26.7%), III (46.7%) and IV (26.7%) were enrolled. 46.7% patients had ECOG PS 1. At data cutoff date (May 08, 2023), 14 patients had at least one post treatment anti-tumor assessment. 1 (7.1%) patient achieved CR, 11 (78.6 %) patients achieved PR, 1 (7.1%) SD and 1 (7.1%) patient NE. The ORR was 85.7%. Median PFS and OS were not reached. Grade ≥3 TRAEs incidence was 42.86% (hypertension: 21.43%, neutropenia: 21.43% leukopenia: 14.29%, and hypertriglyceridemia: 7.14%).
Conclusions
This chemo-less therapy of only 2 cycles of chemotherapy + penpulimab + anlotinib in first-line treatment, maintaining with penpulimab and anlotinib showed promising efficacy with a favourable toxicity profile for patients with persistent, recurrent, or metastatic cervical cancer.
Clinical trial identification
ChiCTR2200062897 (China Clinical Trial Registry).
Editorial acknowledgement
Legal entity responsible for the study
Q. Xu.
Funding
ChiaTai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11